NASDAQ:CDXS - Codexis Stock Price, Price Target & More

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis, Inc. (NASDAQ:CDXS) announced its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.02. The biotechnology company had revenue of $14.04 million for the quarter, compared to analyst estimates of $13.50 million. Codexis had a negative return on equity of 87.65% and a negative net margin of 36.06%. View Codexis' Earnings History.

4 Wall Street analysts have issued 1 year price targets for Codexis' stock. Their predictions range from $11.00 to $18.00. On average, they expect Codexis' share price to reach $14.25 in the next twelve months. This suggests that the stock has a possible downside of 9.2%. View Analyst Ratings for Codexis.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Codexis include Sensient Technologies (SXT), Westlake Chemical Partners (WLKP), Green Plains (GPRE), Renewable Energy Group (REGI), FutureFuel (FF), Green Plains Partners (GPP), REX American Resources (REX), Amyris (AMRS), Sino United Worldwide Consolidated (SUIC), Pacific Ethanol (PEIX), China Insonline (WAYS), Tantech (TANH), Aemetis (AMTX), CTD (CTDH) and Gevo (GEVO).

Media coverage about CDXS stock has been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Codexis earned a news impact score of 0.02 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.63 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Codexis' stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.97%), Comprehensive Portfolio Management LLC (0.11%) and Campbell & CO Investment Adviser LLC (0.02%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Comprehensive Portfolio Management LLC. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Thomas R Baruch and Ventures Vii Affiliates F Vivo. View Insider Buying and Selling for Codexis.

CDXS stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co. and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $15.70.

Codexis has a market capitalization of $838.53 million and generates $50.02 million in revenue each year. The biotechnology company earns $-22,990,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Codexis employs 116 workers across the globe.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]